Form 4: vTv Therapeutics Director Granted Stock Options Valued at $16.59 Per Share

Fahed Al-Marzooqi, a Director at vTv Therapeutics Inc., was granted 4,000 stock options with an exercise price of $16.59 per share, vesting by June 2026.

Summary

• Fahed Al-Marzooqi, a Director of vTv Therapeutics Inc. (VTVT), was granted 4,000 stock options.
• The options have an exercise price of $16.59 per share.
• The transaction date for the grant was June 10, 2025.
• These options will vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders, contingent on the director's continued service.
• The options expire on June 10, 2035.
• Following this transaction, Mr. Al-Marzooqi beneficially owns 13,555 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director's interests with the company's long-term performance, though it's a routine compensation event.

Positives

• The grant of stock options to Director Fahed Al-Marzooqi aligns his interests with those of shareholders, incentivizing long-term performance and retention.

Negatives

• The issuance of new stock options represents potential future dilution for existing shareholders if the options are exercised.

Risks

• The vesting of the options is subject to the director's continued service on the board, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The granted stock options are set to vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders, contingent on the director's continued service, indicating a future incentive structure.

Industry Context

The granting of stock options to directors is a standard practice across various industries, including biotechnology, to attract, retain, and incentivize board members by aligning their financial interests with the long-term performance of the company.

Comparison to Industry Standards

• Granting stock options to directors is a common compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna, Pfizer, or Biogen, which use equity incentives to align director interests with shareholder value.
• The vesting schedule, tied to continued service and a future annual meeting, is typical for director equity awards, comparable to governance practices seen in many publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of 4,000 stock options to Fahed Al-Marzooqi, a Director of vTv Therapeutics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from aligned director incentives.

Next Steps

• The stock options will vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders.

Key Dates

Keywords

vTv Therapeutics, VTVT, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Biotechnology, Pharmaceuticals